- Home
- ESPR vs MSBI Comparison
ESPR vs MSBI Comparison
Compare ESPR & MSBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESPR
- MSBI
- Stock Information
- Founded
- ESPR 2008
- MSBI 1881
- Country
- ESPR United States
- MSBI United States
- Employees
- ESPR N/A
- MSBI N/A
- Industry
- ESPR Biotechnology: Pharmaceutical Preparations
- MSBI Major Banks
- Sector
- ESPR Health Care
- MSBI Finance
- Exchange
- ESPR Nasdaq
- MSBI Nasdaq
- Market Cap
- ESPR 456.6M
- MSBI 505.5M
- IPO Year
- ESPR 2013
- MSBI 2016
- Fundamental
- Price
- ESPR $2.52
- MSBI $27.39
- Analyst Decision
- ESPR Buy
- MSBI Hold
- Analyst Count
- ESPR 3
- MSBI 4
- Target Price
- ESPR $8.17
- MSBI $26.75
- AVG Volume (30 Days)
- ESPR 5.2M
- MSBI 96.1K
- Earning Date
- ESPR 11-07-2024
- MSBI 10-24-2024
- Dividend Yield
- ESPR N/A
- MSBI 4.53%
- EPS Growth
- ESPR N/A
- MSBI N/A
- EPS
- ESPR N/A
- MSBI 2.30
- Revenue
- ESPR $295,451,000.00
- MSBI $259,944,000.00
- Revenue This Year
- ESPR $198.22
- MSBI N/A
- Revenue Next Year
- ESPR $25.83
- MSBI $0.04
- P/E Ratio
- ESPR N/A
- MSBI $11.89
- Revenue Growth
- ESPR 187.12
- MSBI N/A
- 52 Week Low
- ESPR $1.16
- MSBI $20.54
- 52 Week High
- ESPR $3.40
- MSBI $28.47
- Technical
- Relative Strength Index (RSI)
- ESPR 64.07
- MSBI 66.15
- Support Level
- ESPR $2.02
- MSBI $25.75
- Resistance Level
- ESPR $2.60
- MSBI $27.92
- Average True Range (ATR)
- ESPR 0.19
- MSBI 0.76
- MACD
- ESPR 0.02
- MSBI -0.06
- Stochastic Oscillator
- ESPR 89.04
- MSBI 80.80
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The Company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.
About MSBI Midland States Bancorp Inc.
Midland States Bancorp Inc is a diversified financial holding company. The company provides a full range of commercial and consumer banking products and services, business equipment financing, merchant credit card services, trust and investment management, and insurance and financial planning services. The Banking segment which generates the majority of the revenue, provides a wide range of financial products and services to consumers and businesses, including commercial, commercial real estate, mortgage and other consumer loan products; commercial equipment financing etc. The Wealth Management segment consists of trust and fiduciary services, brokerage and retirement planning services. The Other segment includes the operating results of the parent company.